Russia has shared comprehensive data pertaining to its COVID-19 Vaccine Sputnik V with India. Russia has shared details of the vaccine's safety and efficacy.
India had earlier sought the information from Moscow-based Gamaleya Research Institute of Epidemiology and Microbiology, The Indian Express reported, quoting senior officials.
"We are now deeply engaged with Russia on the vaccine front," a source told the newspaper. India also has the option of conducting a separate Phase 3 clinical trial in the country after getting the necessary approvals, the report said.
Moneycontrol could not independently verify the report.
Frequently Asked Questions
A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.
There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.
Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
Results of a study published in The Lancet medical journal revealed that Sputnik V produces an antibody response in all participants in early-stage trials. The two trials were conducted in June-July, according to Reuters, and involved 76 participants. According to the report, it showed that 100 percent of the participants developed anti-bodies, with no serious side-effects.
"Russia's potential COVID-19 vaccine produced an antibody response, no serious adverse effects in early-stage trials," the study said.
India is one of the 20 countries that have expressed interest to be part of Sputnik V’s Phase-3 clinical trials. Earlier, the Russian government had reached out to India seeking collaboration for manufacturing ‘Sputnik V' and conducting its phase III clinical trial.
On August 11, Russia registered what it claims is the first coronavirus vaccine. The COVID-19 vaccine has been jointly developed by the Gamaleya Research Institute and Russia’s Defence Ministry and will be the first vaccine candidate against the novel coronavirus to get registered. It said that mass production of the vaccine will begin in September.
Meanwhile, Defence Minister Rajnath Singh on September 4, during his visit to Moscow for the Shanghai Cooperation Organisation (SCO) meet, said that the coronavirus vaccine being developed by Russia will be effective.
Expressing confidence in the efficacy of Russia’s ‘Sputnik V’ COVID-19 vaccine, the Defence Minister touted the long-running partnership between the two nations.Click here for Moneycontrol's full coverage of the COVID-19 outbreak